Healthcare Industry News: PASCAL Photocoagulator
News Release - November 11, 2006
OptiMedica Launches Suite of Integrated Practice Solutions for the Pascal PhotocoagulatorSANTA CLARA, Calif.--(HSMN NewsFeed)--OptiMedica® Corporation, a leading developer of ophthalmic therapeutic devices, today introduced a new portfolio of products, including the Pascal Laser Indirect Ophthalmoscope (LIO) which was granted marketing clearance by the FDA this month, Automated LaserLog(TM) with treatment summary printout and Intelligent Device Management. These products increase treatment options and efficiencies for the ophthalmic practice and will be showcased this week at the 110th annual American Academy of Ophthalmology (AAO) annual meeting in Las Vegas.
"OptiMedica is committed to delivering the ultimate customer experience," said Dr. David Mordaunt, CEO of OptiMedica. "This includes integrating the best in service with best in products to improve productivity of the entire practice."
The Pascal LIO incorporates superior optics, functional ergonomics and easy-to-use controls. Its built-in device monitoring system provides an added level of safety by designating which delivery method is active and allowing seamless transition between the LIO and the slit lamp. It broadens the use of the PASCAL Photocoagulator for all treatment modalities and situations.
LaserLog saves time and effort by automating treatment documentation and providing printout capability. This software is compatible with any standard PC, facilitating comprehensive documentation of treatment summary and patient ID information as well as physician and CPT codes. In addition, LaserLog increases accuracy and helps avoid missed billing opportunities.
Intelligent Device Management includes real-time online monitoring, diagnosis and troubleshooting. Together, these services provide customers with immediate access to engineering and product management support to ensure a smooth running practice.
OptiMedica can be visited at booth number 2672 at the Sands Expo/Venetian in Las Vegas from November 11 - 13 during the AAO annual meeting. More information about the PASCAL Photocoagulator is available at www.opitmedica.com.
OptiMedica Corp. develops and markets medical devices that treat ophthalmic disorders such as diabetic retinopathy, age-related macular degeneration, retinal vascular occlusive disease and retinal tears and detachments. OptiMedica holds the exclusive license to the PASCAL® (PAttern SCAn Laser) method of photocoagulation and its associated technologies, which are FDA approved to treat a variety of retinal conditions. OptiMedica was founded in 2004 in Santa Clara, Calif. and is funded by Kleiner, Perkins, Caufield & Byers and Alloy Ventures. For more information, please visit www.optimedica.com.
Source: OptiMedica Corp
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.